Abstract
This article examines three aspects of tardive dyskinesia (TD). First, the historical evaluation of TD as a recognized side effect of neuroleptic treatment is examined. Second, the unique ramifications of this side effect for persons who are developmentally disabled are considered. Third, the difficulties presented in prescribing and administering these drugs are examined in light of litigation in the area of TD. Additionally, some results of a national survey on state practices regarding these identified difficulties are reported and analyzed. While a number of states have addressed the issues raised in TD litigation, some states continue to follow practices that disregard these concerns.
Get full access to this article
View all access options for this article.